3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
43
Breast
16
Genitourinary
13
Other hematologic neoplasm
12
Lymphoid
12
CNS
12
Plasma cell
11
Myeloid
11
Dermatologic
10
Sarcoma
3
Gastrointestinal
3
Thoracic
2
Other solid neoplasm
1
Other
1
NET
1
Head & Neck
1
Endocrine
1
Conditions
Neuroendocrine Tumors
378
Carcinoid Tumor
40
Gastro-enteropancreatic neuroendocrine tumor
36
Pancreatic Neoplasms
27
Carcinoma, Neuroendocrine
27
Neoplasms
25
Adenoma, Islet Cell
23
Pheochromocytoma
17
Paraganglioma
17
Neoplasm Metastasis
17
Stomach Neoplasms
15
Neuroblastoma
14
Gastrointestinal Neoplasms
14
Carcinoma, Hepatocellular
12
Thyroid Neoplasms
11
Prostatic Neoplasms
11
Breast Neoplasms
11
Sarcoma
10
Esophageal Neoplasms
10
Colorectal Neoplasms
10
Lung Neoplasms
9
Rectal Neoplasms
8
Gastrointestinal Stromal Tumors
8
Cholangiocarcinoma
8
Carcinoma, Medullary
8
Carcinoma
8
Brain Neoplasms
8
Anus Neoplasms
8
Liver Neoplasms
7
Colonic Neoplasms
7
Interventions
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gestational Trophoblastic Disease
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled